210 related articles for article (PubMed ID: 30663219)
1. Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma.
Schulte L; Scheiner B; Voigtländer T; Koch S; Schweitzer N; Marhenke S; Ivanyi P; Manns MP; Rodt T; Hinrichs JB; Weinmann A; Pinter M; Vogel A; Kirstein MM
Liver Int; 2019 Apr; 39(4):714-726. PubMed ID: 30663219
[TBL] [Abstract][Full Text] [Related]
2. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.
Casadei Gardini A; Faloppi L; De Matteis S; Foschi FG; Silvestris N; Tovoli F; Palmieri V; Marisi G; Brunetti O; Vespasiani-Gentilucci U; Perrone G; Valgiusti M; Granato AM; Ercolani G; Negrini G; Tamburini E; Aprile G; Passardi A; Santini D; Cascinu S; Frassineti GL; Scartozzi M
Eur J Cancer; 2017 Nov; 86():106-114. PubMed ID: 28985579
[TBL] [Abstract][Full Text] [Related]
3. Association of Metformin Use With Cancer-Specific Mortality in Hepatocellular Carcinoma After Curative Resection: A Nationwide Population-Based Study.
Seo YS; Kim YJ; Kim MS; Suh KS; Kim SB; Han CJ; Kim YJ; Jang WI; Kang SH; Tchoe HJ; Park CM; Jo AJ; Kim HJ; Choi JA; Choi HJ; Polak MN; Ko MJ
Medicine (Baltimore); 2016 Apr; 95(17):e3527. PubMed ID: 27124061
[TBL] [Abstract][Full Text] [Related]
4. Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib.
Casadei Gardini A; Marisi G; Scarpi E; Scartozzi M; Faloppi L; Silvestris N; Masi G; Vivaldi C; Brunetti O; Tamberi S; Foschi FG; Tamburini E; Tenti E; Ricca Rosellini S; Ulivi P; Cascinu S; Nanni O; Frassineti GL
Expert Opin Pharmacother; 2015; 16(18):2719-25. PubMed ID: 26513009
[TBL] [Abstract][Full Text] [Related]
5. Metformin does not improve survival in patients with hepatocellular carcinoma.
Bhat M; Chaiteerakij R; Harmsen WS; Schleck CD; Yang JD; Giama NH; Therneau TM; Gores GJ; Roberts LR
World J Gastroenterol; 2014 Nov; 20(42):15750-5. PubMed ID: 25400459
[TBL] [Abstract][Full Text] [Related]
6. Transarterial chemoembolization combined with metformin improves the prognosis of hepatocellular carcinoma patients with type 2 diabetes.
Chen ML; Wu CX; Zhang JB; Zhang H; Sun YD; Tian SL; Han JJ
Front Endocrinol (Lausanne); 2022; 13():996228. PubMed ID: 36187118
[TBL] [Abstract][Full Text] [Related]
7. Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib.
Hsieh MH; Kao TY; Hsieh TH; Kao CC; Peng CY; Lai HC; Chuang PH; Kao JT
PLoS One; 2020; 15(12):e0244293. PubMed ID: 33382703
[TBL] [Abstract][Full Text] [Related]
8. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients.
Nkontchou G; Cosson E; Aout M; Mahmoudi A; Bourcier V; Charif I; Ganne-Carrie N; Grando-Lemaire V; Vicaut E; Trinchet JC; Beaugrand M
J Clin Endocrinol Metab; 2011 Aug; 96(8):2601-8. PubMed ID: 21752887
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: A propensity score analysis.
Costentin CE; Decaens T; Laurent A; Nault JC; Paule B; Letoublon C; Luciani A; Calderaro J; Adam R; Bricault I; Amaddeo G; Cherqui D; Mallat A; Samuel D; Duvoux C; Ganne-Carrié N; Roudot-Thoraval F; Vibert E
Liver Int; 2017 Dec; 37(12):1869-1876. PubMed ID: 28609020
[TBL] [Abstract][Full Text] [Related]
10. Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis.
Zhang XP; Chai ZT; Gao YZ; Chen ZH; Wang K; Shi J; Guo WX; Zhou TF; Ding J; Cong WM; Xie D; Lau WY; Cheng SQ
HPB (Oxford); 2019 Dec; 21(12):1687-1696. PubMed ID: 31153833
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib.
Pinter M; Sieghart W; Hucke F; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Matejka J; Stauber R; Buder R; Grünberger B; Schöniger-Hekele M; Müller C; Peck-Radosavljevic M
Aliment Pharmacol Ther; 2011 Oct; 34(8):949-59. PubMed ID: 21883324
[TBL] [Abstract][Full Text] [Related]
12. Metformin confers risk reduction for developing hepatocellular carcinoma recurrence after liver resection.
Chan KM; Kuo CF; Hsu JT; Chiou MJ; Wang YC; Wu TH; Lee CF; Wu TJ; Chou HS; Lee WC
Liver Int; 2017 Mar; 37(3):434-441. PubMed ID: 27775209
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis: The efficacy of metformin and other anti-hyperglycemic agents in prolonging the survival of hepatocellular carcinoma patients with type 2 diabetes.
Zhou J; Ke Y; Lei X; Wu T; Li Y; Bao T; Tang H; Zhang C; Wu X; Wang G; Li J; Zhang H; Ni F; Ye Z; Wang L
Ann Hepatol; 2020; 19(3):320-328. PubMed ID: 31980358
[TBL] [Abstract][Full Text] [Related]
14. Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic.
Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Michitaka K; Deguchi A; Ishikawa T; Imai M; Ochi H; Joko K; Shimada N; Tajiri K; Hirooka M; Koizumi Y; Hiasa Y; Tanaka J
J Gastroenterol Hepatol; 2019 Jun; 34(6):1066-1073. PubMed ID: 30549320
[TBL] [Abstract][Full Text] [Related]
15. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Lyu N; Kong Y; Mu L; Lin Y; Li J; Liu Y; Zhang Z; Zheng L; Deng H; Li S; Xie Q; Guo R; Shi M; Xu L; Cai X; Wu P; Zhao M
J Hepatol; 2018 Jul; 69(1):60-69. PubMed ID: 29471013
[TBL] [Abstract][Full Text] [Related]
16. Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP.
Tian Y; Tang B; Wang C; Sun D; Zhang R; Luo N; Han Z; Liang R; Gao Z; Wang L
Oncotarget; 2016 Jul; 7(29):46230-46241. PubMed ID: 27323827
[TBL] [Abstract][Full Text] [Related]
17. Metformin reduces the increased risk of oral squamous cell carcinoma recurrence in patients with type 2 diabetes mellitus: A cohort study with propensity score analyses.
Hu X; Xiong H; Chen W; Huang L; Mao T; Yang L; Wang C; Huang D; Wang Z; Yu J; Shu Y; Xia K; Su T
Surg Oncol; 2020 Dec; 35():453-459. PubMed ID: 33065527
[TBL] [Abstract][Full Text] [Related]
18. On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study.
Howell J; Pinato DJ; Ramaswami R; Bettinger D; Arizumi T; Ferrari C; Yen C; Gibbin A; Burlone ME; Guaschino G; Sellers L; Black J; Pirisi M; Kudo M; Thimme R; Park JW; Sharma R
Aliment Pharmacol Ther; 2017 Apr; 45(8):1146-1155. PubMed ID: 28252185
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C.
Harris K; Smith L
Ann Pharmacother; 2013 Oct; 47(10):1348-52. PubMed ID: 24259699
[TBL] [Abstract][Full Text] [Related]
20. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
Wörns MA; Koch S; Niederle IM; Marquardt JU; Nguyen-Tat M; Gamstätter T; Schuchmann M; Schulze-Bergkamen H; Galle PR; Weinmann A
Dig Liver Dis; 2013 May; 45(5):408-13. PubMed ID: 23182599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
